Point-of-Care Industry Expert, Angelo Campano, Joins OptimizeRx Executive Leadership as Senior Vice President and Principal o...
11 Novembre 2020 - 1:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies, physicians and
patients, has appointed Angelo Campano to the new position of
senior vice president and principal of agency channels.
Campano will be responsible for driving the strategic growth and
expansion of OptimizeRx partnerships with healthcare advertising
agencies. This includes implementing point-of-care engagement
programs designed for specific populations of patients and
providers.
“Angelo is an incredibly well-respected thought leader,
innovator and strategist in point-of-care solutions, and we are
honored to have him join our team,” said Steve Silvestro, chief
commercial officer at OptimizeRx. “His proven ability to develop
partnerships that bring digital touchpoints together at the
point-of-care greatly complements our mission of helping life
sciences be present throughout the care journey.
“As we evolve our platform to meet the growing need for
connectivity and even greater focus on specialty medications,
Angelo’s expertise will help us drive even more growth and
accelerate innovation in the collaboration between healthcare
stakeholders.”
The OptimizeRx digital health and communication platform
connects the treatment support of life sciences to all stages of a
patient’s care journey, and helps people afford and stay on
medications through the doctor-recommended course of treatment.
The company’s point-of-care expansions this year include
partnerships with Change Healthcare and Epion. It has also added
point-of-dispense touchpoints through a new partnership with Higi,
which represents innovative new modes of delivery for healthcare
advertising agencies who are looking to serve valuable support
content on behalf of life science organizations. It has also added
point-of-dispense touchpoints through a new partnership with Higi,
which represents innovative new modes of delivery for healthcare
advertising agencies who are looking to serve valuable support
content on behalf of life science organizations.
“I am excited to join the OptimizeRx team at this pivotal stage
of the company’s growth and expansion at the point of care,”
commented Campano. “I’ve spent my career deeply embedded in channel
communications for life sciences, and I’ve witnessed OptimizeRx
grow and innovate tremendously. It is a natural step for me to
build on the work I’ve done connecting siloed pockets of healthcare
providers and enabling more effective distribution of life sciences
support.”
Campano has been a trailblazer in innovation and leadership in
electronic health record (EHR) workflow and hub services. Prior to
joining OptimizeRx, he served as senior vice president for point of
care marketing at Ogilvy Health, where he created a proprietary
business rules engine that enables specific interactions across
multiple EHR platforms and eliminates the fragmentation of
healthcare provider reach. He has established partnerships with
more than 245 EHR platforms, 100 specialty pharma partners and five
communications partners to bring life sciences resources to more
places at the point-of-care.
Campano received a bachelor’s degree in bioinformatics from
Rutgers University. He was inducted into the Medical Advertising
Hall of Fame in 2014 as a Future Hall of Famer, and was the
recipient of the PM360’s ELITE Innovator Award in 2017.
About OptimizeRxOptimizeRx is a digital health
company that provides communications solutions for life science
companies, physicians and patients. Connecting over half of
healthcare providers in the U.S. and millions of patients through a
proprietary network, the OptimizeRx digital health platform helps
patients afford and stay on medications. The platform unlocks new
patient and physician touchpoints for life science companies along
the patient journey, from point-of-care, to retail pharmacy,
through mobile patient engagement.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
OptimizeRx Contact Doug Baker, CFOTel
(248) 651-6568 (x807)dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Investor Relations Contact Ron Both,
CMA Tel (949) 432-7557 oprx@cma.team
Grafico Azioni OptimizeRx (NASDAQ:OPRX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OptimizeRx (NASDAQ:OPRX)
Storico
Da Lug 2023 a Lug 2024